Intuitive Surgical (NASDAQ:ISRG) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Intuitive Surgical (NASDAQ:ISRG) had its price objective raised by analysts at JPMorgan Chase & Co. from $450.00 to $475.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 10.59% from the stock’s previous close.

A number of other research analysts have also issued reports on the stock. Truist Financial reduced their target price on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Royal Bank Of Canada decreased their target price on shares of Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a research report on Wednesday. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $454.00 price target on shares of Intuitive Surgical in a report on Wednesday. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $480.00 price target on shares of Intuitive Surgical in a report on Wednesday. Twenty-five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $498.31.

Intuitive Surgical Stock Performance

Shares of ISRG traded down $8.47 during midday trading on Wednesday, hitting $429.53. 2,088,937 shares of the stock traded hands, compared to its average volume of 2,412,223. Intuitive Surgical has a 1-year low of $328.57 and a 1-year high of $603.88. The firm has a market capitalization of $151.74 billion, a PE ratio of 48.97, a price-to-earnings-growth ratio of 3.27 and a beta of 1.46. The business’s 50 day moving average price is $392.96 and its two-hundred day moving average price is $409.06.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the prior year, the firm earned $2.40 earnings per share. The company’s quarterly revenue was up 21.7% on a year-over-year basis. As a group, equities research analysts forecast that Intuitive Surgical will post 8.87 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares in the company, valued at approximately $2,016,280. The trade was a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the sale, the director directly owned 1,245,679 shares in the company, valued at $498,271,600. This trade represents a 0.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 12,370 shares of company stock worth $4,891,989. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Intuitive Surgical

Several institutional investors have recently made changes to their positions in ISRG. Plato Investment Management Ltd purchased a new stake in shares of Intuitive Surgical during the second quarter worth $4,315,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Intuitive Surgical during the second quarter valued at $14,316,000. Hikari Power Ltd purchased a new position in Intuitive Surgical in the second quarter valued at about $5,619,000. Nykredit A S purchased a new position in Intuitive Surgical in the second quarter valued at about $48,464,000. Finally, NewEdge Advisors LLC grew its stake in Intuitive Surgical by 19.1% in the second quarter. NewEdge Advisors LLC now owns 50,825 shares of the medical equipment provider’s stock valued at $20,212,000 after purchasing an additional 8,142 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Underlying operating results were strong: revenue increased 21.7% year over year to $3.05 billion, while adjusted earnings reached $3.00 per share versus consensus estimates near $2.61–$2.65. Worldwide procedures grew approximately 15%, and da Vinci system placements rose to 546 from 427 a year earlier. Intuitive Surgical’s Q3 Earnings Beat Estimates on Strong System Sales
• Positive Sentiment: Analyst support remains broadly favorable. Bernstein reaffirmed a Buy rating with a $685 target, BTIG maintained Buy, Baird raised its target to $550, and Erste Group upgraded the stock from Hold to Buy. ISRG also crossed above its 200-day moving average, a technical signal that can indicate improving long-term momentum. Bernstein Reaffirms Buy Rating
• Neutral Sentiment: Analyst revisions were mixed after the report. RBC lowered its target to $550 but kept Outperform, Raymond James trimmed its target to $480, and Mizuho cut its target to $400 with a Neutral rating. RBC Capital Adjusts Price Target
• Negative Sentiment: A $450 million pretax charge tied to a proposed antitrust settlement reduced GAAP earnings to $1.49 per share from $1.95 a year earlier. The settlement remains subject to court approval, adding legal and financial uncertainty. Intuitive Surgical Stock Slides Despite Earnings Beat
• Negative Sentiment: Management narrowed its 2026 da Vinci procedure-growth forecast to 14%–15% and plans pricing actions that could reduce revenue per procedure by 3%–5%. Reports also highlighted a U.S. procedure slowdown, increasing concern that growth may moderate despite continued system demand. Intuitive Narrows 2026 Procedure Growth Outlook

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.